ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1723

Nuclear Magnetic Resonance Based Metabolomics Study Identifies Highly Discriminatory Metabolites in 87 Systemic Sclerosis Patients

Sakir Ahmed1, Mohit Kumar Rai1, Durgesh Dubey2, Atul Rawat3, Dinesh Kumar3, Durga Prasanna Misra1 and Vikas Agarwal1, 1Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 2Centre for Biomedical Research, PhD Student, Lucknow, India, 3Centre for Biomedical Research, Lucknow, India

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Biomarkers, metabolomics and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Nuclear Magnetic Resonance based Metabolomics Study Identifies Highly Discriminatory Metabolites in 87 Systemic Sclerosis Patients

Background/Purpose:

Proton based Nuclear Magnetic Resonance (1H NMR) can identify concentration of hundreds of small molecules in body fluids. A hypothesis-free approach was used to analyze metabolic perturbations in sera of Systemic Sclerosis (SSc) to identify potential biomarkers of the disease.

Methods:

Sera from 87 patients meeting ACR 1980 criteria for Systemic Sclerosis, and 40 age and sex similar controls, was analyzed using 1H NMR spectroscopy coupled with multivariate statistical analysis.

Results:

There was clear distinction between SSc and healthy controls on Partial Least Square-Discriminate Analysis (PLS-DA) [R2= 0.98]. Several metabolites of discriminatory relevance were  identified, and further evaluated using analysis of variance (ANOVA) and Receiver Operator Curve (ROC) analysis. Methylamine, nitrosodimethylamine (NDMA), citrate and malonate were 4 metabolites that had maximum area under curve (AUC> 0.95) in distinguishing SSc from controls [Figure 2]. Methylamine and NDMA were uniformly elevated almost exclusively in SSc patients. Figure 3 shows Orthogonal PLS-DA of limited versus diffuse disease; or patients with or without interstitial lung disease (ILD).

Conclusion:

H1 NMR based metabolomics identified metabolites that have high discriminate value for SSc. The potential of these molecules as biomarkers, or their possible roles in disease pathogenesis need to be explored.

 


Disclosure: S. Ahmed, None; M. K. Rai, None; D. Dubey, None; A. Rawat, None; D. Kumar, None; D. P. Misra, None; V. Agarwal, None.

To cite this abstract in AMA style:

Ahmed S, Rai MK, Dubey D, Rawat A, Kumar D, Misra DP, Agarwal V. Nuclear Magnetic Resonance Based Metabolomics Study Identifies Highly Discriminatory Metabolites in 87 Systemic Sclerosis Patients [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/nuclear-magnetic-resonance-based-metabolomics-study-identifies-highly-discriminatory-metabolites-in-87-systemic-sclerosis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nuclear-magnetic-resonance-based-metabolomics-study-identifies-highly-discriminatory-metabolites-in-87-systemic-sclerosis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology